Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes

EMPA-HEART Cardiolink-6 trial results suggest that the SGLT2 inhibitor is linked to reduced left ventricular mass, a surrogate for reduced heart failure, in patients with CVD and type 2 diabetes.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news

Related Links:

A fair amount of effort is presently put towards the exploration of supplements derived from vitamin B3 compounds (nicotinamide, niacin, nicotinamide riboside) that act as precursors to enable the manufacture of nicotinamide adenine dinucleotide (NAD). NAD is an important component in mitochondrial activity, and levels decline with age. Some portion of the loss of mitochondrial function, implicated in the progression of many age-related conditions, is due to NAD insufficiency. There is a rich history of the use of high doses of vitamin B3 as an intervention, most of it predating modern understanding of the role of NAD in m...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Accumulation of methylglyoxal (MG) contributes to oxidative stress, apoptosis, and mitochondrial dysfunction, leading to the development of type 2 diabetes and cardiovascular diseases. Inhibition of mitochondrial abnormalities induced by MG in the heart may improve and delay the progression of heart failure. Although glucagon-like peptide-1 receptor (GLP-1R) agonists have been used as anti-diabetic drugs and GLP-1R has been detected in the heart, the cardioprotective effects of GLP-1R agonists on the inhibition of MG-induced oxidative stress and mitochondrial abnormalities have not been elucidated. Stimulation of GLP-1Rs l...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
The effects of sodium-glucose cotransporter 2 inhibitor (SGLT2i) on cardiac function are not fully understood. We investigated the changes in cardiac function in diabetic patients according to the presence and...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research
This article aims to review the key connections in the epidemiology and etiopathophysiology of type 2 diabetes and heart failure
Source: Clinics in Geriatric Medicine - Category: Geriatrics Authors: Source Type: research
AbstractType 2 diabetes mellitus (T2DM) is a known predisposing factor for heart failure (HF). The growing burden of these two conditions and their impact on health of the individual and on society in general needs urgent attention from the health care professionals. Availability of multiple treatment choices for managing T2DM and HF may make therapeutic decisions more complex for clinicians. Recent cardiovascular outcome trials of antidiabetic drugs have added very robust evidence to effectively manage subjects with this dual condition. This consensus statement provides the prevalence trends and the impact of this dual bu...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
ConclusionsOur findings suggest that empagliflozin prescribed for preventing CV death or hHF in T2DM patients seems to be cost saving compared to treatment with canagliflozin, and dapagliflozin.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
AbstractThe heart failure (HF) epidemic is growing and approximately half of the HF patients have heart failure with preserved ejection fraction (HFpEF). HFpEF is a heterogeneous syndrome, characterized by a preserved left ventricular ejection fraction (LVEF ≥ 50%) with diastolic dysfunction, and is associated with high morbidity and mortality. Underlying comorbidities of HFpEF, i.e., hypertension, type 2 diabetes mellitus, obesity, and renal failure, lead to a systemic pro-inflammatory state, thereby affecting normal cardiac function. Increased inf lammatory biomarkers predict incident HFpEF and are higher in pa...
Source: Journal of Cardiovascular Translational Research - Category: Cardiology Source Type: research
PMID: 32433044 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
ConclusionEmpagliflozin treatment preserves mitochondrial fatty acid oxidation in the heart under conditions of chronic lipid overload.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
AbstractHeart failure is a growing health issue as a negative consequence of improved survival upon myocardial infarction, unhealthy lifestyle, and the ageing of our population. The large and complex pathology underlying heart failure makes diagnosis and especially treatment very difficult. There is an urgent demand for discriminative biomarkers to aid disease management of heart failure. Studying cellular pathways and pathophysiological mechanisms contributing to disease initiation and progression is crucial for understanding the disease process and will aid to identification of novel biomarkers and potential therapeutic ...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Review Source Type: research
More News: Cardiology | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Health | Heart | Heart Failure | Jardiance | SGLT2 Inhibitors